IBM ($IBM) has landed a 5-year $75 million FDA contract to help the agency modernize its regulatory review process by ramping up the agency's computation science capabilities. IBM will analyze regulatory submissions the agency receives from pharmaceutical, medical device and biologic manufacturers with the goal of having an "end-to-end process" that allows FDA to not just have access to industry data, but also the tools needed to analyze it throughout a product's lifespan. Item